You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020202016
Dec 20203008
Jan 20211008
Feb 20211804
Mar 20212406
Apr 20212602
May 2021504
Jun 2021009
Jul 2021002
Aug 2021004
Sep 2021005
Oct 202118022
Nov 202120018
Dec 20211203
Jan 20221803
Feb 20221802
Mar 20222601
Apr 20224601
May 20222807
Jun 202248016
Jul 20222403
Aug 20222803
Sep 20223009
Oct 20221402
Nov 20221600
Dec 20222403
Jan 20231801
Feb 20232202
Mar 20231601
Apr 20231408
May 20231000
Jun 20231402
Jul 20232204
Aug 2023601
Sep 20231406
Oct 20231404
Nov 20232209
Dec 20234802
Jan 20242403
Feb 20242001
Mar 20243201
Apr 20241001
May 20243205
Jun 20246004
Jul 202456011
Aug 202420010
Sep 20242207
Oct 202412011
Nov 202418012
Dec 20241405
Jan 2025806
Feb 2025609
Mar 2025007
Apr 2025006
May 20250014
Jun 20250010
Total12390324